Revolution Medicines

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revolution Medicines reports positive clinical progress and financial stability

Revolution Medicines made significant strides in clinical development and financial stability, despite anticipating increased expenses in 2023
Confidence in the efficacy and tolerability of RMC-6236 and RMC-6291, with a focus on optimizing dosing strategies for future development
Challenges include financial projections for 2023, patient evaluation discrepancies, and the need for more data on dose levels and response rates
Opportunities lie in exploring intermittent dosing, discussing specific response rates, and further data collection for dose optimization

Revolution Medicines reports promising antitumor activity and strengthens financial position

Revolution Medicines showcased progress in their innovative inhibitor programs, bolstered by a successful equity offering. While facing competition and addressing analyst concerns, the company is poised to deliver significant clinical updates and expand their data set for future growth.

Revolution Medicines reports Q2 progress, acquires EQRx for growth

Revolution Medicines showcased financial strength, pipeline progress, and strategic acquisitions, positioning the company for future growth.
While facing challenges in managing expenses and advancing drug candidates, opportunities in pivotal trials and partnerships present avenues for success.
Overall, Revolution Medicines remains optimistic about its clinical developments and financial stability, signaling a promising trajectory in the biopharmaceutical sector.

Revolution Medicines reports strong Q3 results and strategic investment plans

Revolution Medicines showcased promising drug results, bolstered its financial position through an acquisition, and emphasized strategic spending for value creation. Analyst inquiries highlighted the importance of clear communication and effective financial planning for future success.

Revolution Medicines reports robust 2023 performance and strategic growth

Revolution Medicines showcased strong financial performance and progress in 2023.
The company faces challenges in revenue and net loss but sees opportunities in global partnerships and drug combinations.
Strategic priorities for 2024 focus on advancing RAS inhibitors and expanding reach.
Overall, Revolution Medicines is positioned for growth despite facing financial and developmental challenges.

Revolution Medicines advances pivotal cancer trials amidst financial projections

Revolution Medicines is well-capitalized and focused on advancing key therapies.
Facing financial challenges but exploring partnerships and business growth.
Opportunities lie in expanding RMC-6236's efficacy and exploring new indications.

Revolution Medicines excels in Q2 with RAS(ON) inhibitor progress

Revolution Medicines' Q2 performance reflects strong advancements in oncology treatments, supported by a solid financial position and strategic leadership decisions.
While facing challenges in trial execution and financial management, the company's focus on innovation and growth presents significant opportunities for expansion.
Overall, Revolution Medicines is well-positioned to capitalize on the potential of its RAS(ON) inhibitor pipeline and drive future success in the biopharmaceutical industry.

Revolution Medicines reports Q3 loss but shows promise in cancer treatments

Revolution Medicines showcased progress in cancer treatments despite a net loss in Q3 2024. Strong cash reserves, promising data, and strategic collaborations position the company for future growth. Clear communication on financial strategies and upcoming milestones will be crucial for investor confidence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines, Inc. (RVMD) CEO Dr. Mark Goldsmith on Q2 2021 Results - Earnings Call Transcript

Shares of Revolution Medicines (NASDAQ:RVMD) fell 8.0% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 30.43% year over year to ($0.60), which missed the estimate of ($0.56).

Revolution Medicines: Q2 Earnings Insights

Company Shows Continued Progress Demonstrating Differentiation of RAS(ON) Inhibitors, Targeting Additional RAS Variants and Progressing Assets Toward the Clinic

Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress

Conference Call and Webcast Scheduled for Wednesday, August 11, 2021 at 4:30 p.m. Eastern Time Conference Call and Webcast Scheduled for Wednesday, August 11, 2021 at 4:30 p.m. Eastern Time

Revolution Medicines to Report Financial Results for Second Quarter 2021 After Market Close on August 11, 2021

Revolution Medicines, Inc. (RVMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Revolution Medicines, Inc. (RVMD) Q2 Earnings Expected to Decline

Findings Published in Nature Chemical Biology Support Clinical Development of RMC-5552, the Company's First-in-Class, Phase 1/1b Bi-steric mTORC1-Selective Inhibitor Findings Published in Nature Chemical Biology Support Clinical Development of RMC-5552, the Company's First-in-Class, Phase 1/1b Bi-steric mTORC1-Selective Inhibitor

Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1

Emerging Insights about RAS-Addicted Cancers, Drug Resistance and Treatment Strategies Emerging Insights about RAS-Addicted Cancers, Drug Resistance and Treatment Strategies

Revolution Medicines to Host Science Talk Webcast Highlighting Learnings from Recent Preclinical and Clinical Studies of RAS Inhibitors

REDWOOD CITY, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in the upcoming Goldman Sachs 42nd Annual Global Healthcare Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a fireside chat at the event.

Revolution Medicines to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

REDWOOD CITY, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that the company will participate in the upcoming Cowen 2nd Annual Virtual Oncology Innovation Summit. Steve Kelsey, M.D., president, research and development, will be the featured speaker in a fireside chat at the event.

Revolution Medicines to Participate in Cowen 2nd Annual Virtual Oncology Innovation Summit

Multiple AACR Presentations Highlight Potential Advantages of RAS(ON) Inhibitors;  Scientific Publication is First to Demonstrate Anti-Drug Resistance Features

Revolution Medicines Reports First Quarter Financial Results and Update on Corporate Progress

Revolution Medicines, Inc. (RVMD) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Flavia Borellini, Ph.D., Distinguished Precision Oncology Drug Development Leader, Joins Existing Board Members Elizabeth McKee Anderson and Neil Exter as Class I Director Nominees Flavia Borellini, Ph.D., Distinguished Precision Oncology Drug Development Leader, Joins Existing Board Members Elizabeth McKee Anderson and Neil Exter as Class I Director Nominees

Revolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting

First-in-Class Bi-steric mTORC1 Inhibitor Advances into Clinical Development

Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors

Revolution Medicines' leading compound is shaping up to be a platform in a pill.

This 2020 Biotech IPO Is Poised to Break Out in 2021

Presentations Highlight Continued Progress Across Expanded R&D Pipeline of RAS(ON) Inhibitors and RAS Companion Inhibitors Presentations Highlight Continued Progress Across Expanded R&D Pipeline of RAS(ON) Inhibitors and RAS Companion Inhibitors

Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021

Advanced and Expanded Portfolio of RAS(ON) Inhibitors; Two Assets Entered IND-Enabling Development

Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress

Steve Kelsey, M.D., President, Research and Development, to Present its Pioneering RAS(ON) Inhibitors and Participate in Panel Discussion Steve Kelsey, M.D., President, Research and Development, to Present its Pioneering RAS(ON) Inhibitors and Participate in Panel Discussion

Revolution Medicines to Participate in Digital RAS-Targeted Drug Discovery Summit and Upcoming Investor Conferences

Revolution Medicines Inc (NASDAQ: RVMD) has priced its upsized underwritten public offering of around 5.8 million common shares at $45 per share, equivalent to gross proceeds of $260.9 million. Previously, the company had offered to sell 4 million shares.

Revolution Medicines Raises $260.9 Million In Upsized Offering

REDWOOD CITY, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD) today announced the pricing of its underwritten public offering of 5,797,101 shares of common stock at a public offering price of $45.00 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by Revolution Medicines. In addition, Revolution Medicines has granted the underwriters a 30-day option to purchase up to an additional 869,565 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Revolution Medicines, are expected to be approximately $260.9 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on February 8, 2021, subject to customary closing conditions.

Revolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common Stock

REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD) today announced that it has commenced an underwritten public offering of 4,000,000 shares of common stock. All of the shares of common stock are being offered by Revolution Medicines. In addition, Revolution Medicines intends to grant the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock.

Revolution Medicines Announces Proposed Public Offering of Common Stock

REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman, will deliver a corporate presentation as part of the 39th Annual J.P. Morgan Healthcare Conference. The conference, which will take place January 11-14, 2021, is being conducted with a virtual format.

Revolution Medicines to Provide R&D Pipeline Update, Including Progress of RAS(ON) Inhibitor Programs, During Presentation at 39th Annual J.P. Morgan Healthcare Conference

Revolution Medicines (NASDAQ: RVMD) shares are trading higher on Thursday after the company reported a third-quarter EPS loss of 42 cents, up from a loss of $6.08 year-over-year and sales $12.66 million up from $12.51 million year-over-year. Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways.

Why Revolution Medicines Stock Is Trading Higher

Recommended Phase 2 Dose and Schedule Selected for Further Evaluation of RMC-4630 as Monotherapy and RMC-4630 plus Cobimetinib Combination

Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress

Plenary Presentation at EORTC-NCI-AACR 3 2 nd Symposium on Molecular Targets and Cancer Therapeutics Describes Encouraging Tolerability and Exposure Profile s for RMC-4630 Combined with Cobimetinib and Early Evidence of Clinical Activity in RAS mut C olorectal Ca ncers

Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers

Study Findings Selected for Oral Presentation in Plenary Session at EORTC-NCI-AACR 32nd Symposium on Molecular Targets and Cancer Therapeutics Study Findings Selected for Oral Presentation in Plenary Session at EORTC-NCI-AACR 32nd Symposium on Molecular Targets and Cancer Therapeutics

Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors

News for Revolution Medicines Stock (RVMD)